Tags

Type your tag names separated by a space and hit enter

SmartPlug in the management of severe dry eye syndrome.
Cornea 2007; 26(5):534-8C

Abstract

PURPOSE

To evaluate long-term efficacy and safety of the SmartPlug in the management of severe dry eye syndrome.

METHODS

A retrospective chart review was conducted of patients who underwent SmartPlug insertion from June 2003 to December 2005. The clinical data collected included sex and age of the patients, indications for plug insertion, Schirmer tear function test with anesthesia, frequency of lubricant eye drop use before and after plug insertion, fluorescein staining at baseline and at last follow-up, and complications.

RESULTS

There were 91 eyes of 54 patients (44 women and 10 men) in the study group. The average follow-up period was 13.0 +/- 6.0 months, with a minimum of 6 months. Thirty patients (55 eyes, 60.4%) reported a decreased use of lubricant eye drops after SmartPlug insertion, including 9 patients (14 eyes, 15.4%) who were free of supplementary lubricant eye drops. Forty-one patients (69 eyes, 75.8%) reported subjective symptom improvement after SmartPlug insertion. The corneal fluorescein staining showed overall reduction. Complications included canaliculitis (6 eyes, 6.6%), epiphora requiring plug removal (5 eyes, 5.5%), and spontaneous plug loss (2 eyes, 2.2%).

CONCLUSIONS

SmartPlug can be effective in the management of severe dry eye syndrome. However, long-term follow-up is needed for potentially serious complications such as canaliculitis.

Authors+Show Affiliations

Department of Ophthalmology, Royal Brisbane Hospital, Herston, Queensland, Australia.No affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

17525646

Citation

Chen, Simon X., and Graham A. Lee. "SmartPlug in the Management of Severe Dry Eye Syndrome." Cornea, vol. 26, no. 5, 2007, pp. 534-8.
Chen SX, Lee GA. SmartPlug in the management of severe dry eye syndrome. Cornea. 2007;26(5):534-8.
Chen, S. X., & Lee, G. A. (2007). SmartPlug in the management of severe dry eye syndrome. Cornea, 26(5), pp. 534-8.
Chen SX, Lee GA. SmartPlug in the Management of Severe Dry Eye Syndrome. Cornea. 2007;26(5):534-8. PubMed PMID: 17525646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SmartPlug in the management of severe dry eye syndrome. AU - Chen,Simon X, AU - Lee,Graham A, PY - 2007/5/26/pubmed PY - 2007/8/8/medline PY - 2007/5/26/entrez SP - 534 EP - 8 JF - Cornea JO - Cornea VL - 26 IS - 5 N2 - PURPOSE: To evaluate long-term efficacy and safety of the SmartPlug in the management of severe dry eye syndrome. METHODS: A retrospective chart review was conducted of patients who underwent SmartPlug insertion from June 2003 to December 2005. The clinical data collected included sex and age of the patients, indications for plug insertion, Schirmer tear function test with anesthesia, frequency of lubricant eye drop use before and after plug insertion, fluorescein staining at baseline and at last follow-up, and complications. RESULTS: There were 91 eyes of 54 patients (44 women and 10 men) in the study group. The average follow-up period was 13.0 +/- 6.0 months, with a minimum of 6 months. Thirty patients (55 eyes, 60.4%) reported a decreased use of lubricant eye drops after SmartPlug insertion, including 9 patients (14 eyes, 15.4%) who were free of supplementary lubricant eye drops. Forty-one patients (69 eyes, 75.8%) reported subjective symptom improvement after SmartPlug insertion. The corneal fluorescein staining showed overall reduction. Complications included canaliculitis (6 eyes, 6.6%), epiphora requiring plug removal (5 eyes, 5.5%), and spontaneous plug loss (2 eyes, 2.2%). CONCLUSIONS: SmartPlug can be effective in the management of severe dry eye syndrome. However, long-term follow-up is needed for potentially serious complications such as canaliculitis. SN - 0277-3740 UR - https://www.unboundmedicine.com/medline/citation/17525646/SmartPlug_in_the_management_of_severe_dry_eye_syndrome_ L2 - http://dx.doi.org/10.1097/ICO.0b013e318038d2cd DB - PRIME DP - Unbound Medicine ER -